Doyle John Brendan 4

What Happened John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics (CGTX), received an award of 200,000 restricted stock units (RSUs) on 2026-02-03 (acquisition code A). On 2026-02-04 the company withheld 26,921 shares to satisfy tax withholding obligations related to the RSU vesting; those shares were recorded as disposed at $1.03 each for a total withholding value of $27,729. The RSUs are contingent rights to receive common shares upon settlement and are not an open-market purchase.

Key Details

• Grant: 200,000 RSUs granted on 2026-02-03 (acquisition at $0.00 per share).
• Withholding: 26,921 shares withheld on 2026-02-04 at $1.03 each = $27,729 (tax withholding, disposition code F).
• Footnotes: F1 — each award is an RSU representing a contingent right to one share on settlement; F2 — withheld shares were to cover tax withholding on RSU vesting.
• Form 4 filed: 2026-02-05. No late-filing flag provided in the supplied details.
• Shares owned after the transactions: not specified in the provided filing summary.

Context RSU grants are non-cash compensation that convert to actual shares only upon settlement/vesting. Share withholding to cover taxes is a routine administrative step (a form of cashless settlement) and reflects tax obligations rather than an open-market sale signaling sentiment.